IRVINE, Calif. (PRWEB)
April 12, 2023
Fluxergy, a medical diagnostic company focused on multimodal point-of-care testing, updated stakeholders that 115 Fluxergy Analyzers have been installed in the field at the time of this press release. 60 of these installations are in the company’s expanding equine veterinary sector, where Fluxergy is the first to launch point-of-care molecular technology. The rising number of Analyzers in use marks large growth for the point-of-care company since its founding in 2013. Fluxergy intends to increase in-field Fluxergy Analyzer installations and develop new testing assays to address biosecurity and general equine health.
The recent outbreaks of EHV-1 highlighted the need for equine infectious disease rapid testing, as these outbreaks led to equestrian competition closures and large loss of revenues. Fluxergy’s platform finds practical application in larger equine veterinary hospitals, show grounds, racetracks, and research labs. Key partners, including the UC Davis Equine Infectious Disease Research Laboratory, provide key R&D insights as well as collaboration in future assay development. Fluxergy currently has over 50 multi-doctor practices in the US, Canada, and EU that are evaluating or using their products.
Fluxergy offers a 60-minute* Environmental Salmonella PCR to help protect the veterinary hospital environment. Customer clinics reported more frequent and routine testing with Fluxergy’s system as a key factor in improved biosecurity. Fluxergy’s EHV-1 assay is pending USDA approval and is under evaluation with participating clinicians through an experimental permit. Future assays include Streptococcus equi equi, a multiplex equine respiratory panel, a total nucleated cell count, and an inflammation panel. Fluxergy intends to continue developing assays both in-house and through a collaborative model, with partners assisting in creating custom assays to address their specific clinical needs around the globe. Potential applications include reproductive health, endocrine diseases, and enteric pathogens.
Fluxergy also announces their partnership with Dr. Nicola Pusterla, (DVM, PhD, D ACVIM, DACVD-Equine) principal investigator of the UC Davis Equine Infectious Disease Research Laboratory as a core scientific advisor. A longtime supporter of Fluxergy’s technology, Dr. Pusterla brings a wealth of knowledge surrounding infectious equine diseases and diagnostics. With this additional support, Fluxergy strives to better address the lack of rapid testing for equine diseases.
“The limiting factor for all equine practitioners today is time. By the time a result comes back from the lab, the result is often meaningless when it comes to contagious infectious diseases. We need to change the dogma of sending diagnostic samples to the lab to bringing POC assays to the stall in order to aid in rapid diagnosis and appropriate treatment. It’s been exciting working with the team at Fluxergy thus far, and I am eager to continue pushing the science behind their patient-side detection technologies.”
*60-minutes after enrichment
About Fluxergy
Fluxergy is a medical device manufacturing company specializing in point-of-use detection technologies with the goal of making affordable diagnostics accessible in all settings. The Fluxergy system uses patented microfluidics and a highly integrated sensor system to produce a more flexible and cost-effective multimodal testing platform. Fluxergy is actively seeking strategic investors, assay development partners, and distribution partners with motivation to improve diagnostic access in veterinary medicine.
The Fluxergy Analyzer is available through http://www.fluxergy.com today.
For more information, contact:
Eric Mendonsa, Director of Business Development
+1 (949) 305-4201 ext. 507
Emendonsa@fluxergy.com
Share article on social media or email: